Search

Your search keyword '"Howard L, McLeod"' showing total 270 results

Search Constraints

Start Over You searched for: Author "Howard L, McLeod" Remove constraint Author: "Howard L, McLeod" Topic medicine.disease Remove constraint Topic: medicine.disease
270 results on '"Howard L, McLeod"'

Search Results

1. Identification of Targetable Gene Fusions and Structural Rearrangements to Foster Precision Medicine inKRASWild-Type Pancreatic Cancer

2. β-adrenergic receptor inhibition enhances oncolytic herpes virus propagation through STAT3 activation in gastric cancer

Catalog

Books, media, physical & digital resources

3. Race and smoking status associated with paclitaxel drug response in patient-derived lymphoblastoid cell lines

4. Genomewide Meta‐Analysis Validates a Role for S1PR1 in Microtubule Targeting Agent‐Induced Sensory Peripheral Neuropathy

5. High levels of tumor-infiltrating lymphocytes showed better clinical outcomes in FOLFOX-treated gastric cancer patients

6. Propranolol Suppresses the Growth of Colorectal Cancer Through Simultaneously Activating Autologous CD8 + T Cells and Inhibiting Tumor AKT/MAPK Pathway

7. Role for Nucleotide Excision Repair Gene Variants in Oxaliplatin-Induced Peripheral Neuropathy

8. β-Adrenergic Receptor Inhibitor and Oncolytic Herpesvirus Combination Therapy Shows Enhanced Antitumoral and Antiangiogenic Effects on Colorectal Cancer

9. Effect of Physician-Pharmacist Participation in the Management of Ambulatory Cancer Pain Through a Digital Health Platform: Randomized Controlled Trial

10. Prioritization of Therapy Options for a Patient With High Tumor Mutation Burden and Microsatellite Instability but No Clinical Benefit From Immunotherapy

11. The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy

12. Rates and Risk of Atrial Arrhythmias in Patients Treated With Ibrutinib Compared With Cytotoxic Chemotherapy

13. Influence of genetic variation in the vitamin D pathway on plasma 25-hydroxyvitamin D3 levels and survival among patients with metastatic colorectal cancer

14. Pharmacogenetic study in gastric cancer patients treated with adjuvant fluorouracil/leucovorin or epirubicin/cisplatin/fluorouracil before and after chemoradiation on CALGB 80101 (Alliance)

15. Clinical Use of Propranolol Reduces Biomarkers of Proliferation in Gastric Cancer

16. Large-Scale Meta-Analysis of Potential Biomarkers for Treatment Response to Anti-PD-1/PD-L1 Immune Checkpoint Inhibitors

17. A Type 2 Diabetes Subtype Responsive to ACCORD Intensive Glycemia Treatment

18. Genomic Analysis of Germline Variation Associated with Survival of Patients with Colorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405 (Alliance)

19. A Pharmacogenetic Prediction Model of Progression‐Free Survival in Breast Cancer using Genome‐Wide Genotyping Data from <scp>CALGB</scp> 40502 (Alliance)

20. Genome-scale analysis identifies SERPINE1 and SPARC as diagnostic and prognostic biomarkers in gastric cancer

21. Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance)

22. Genetic Variants in CPA6 and PRPF31 Are Associated With Variation in Response to Metformin in Individuals With Type 2 Diabetes

23. Tumor exome sequencing and copy number alterations reveal potential predictors of intrinsic resistance to multi-targeted tyrosine kinase inhibitors

24. Key Lessons Learned from Moffitt’s Molecular Tumor Board: The Clinical Genomics Action Committee Experience

25. Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study

26. Synergistic Chemotherapy Drug Response Is a Genetic Trait in Lymphoblastoid Cell Lines

27. Adherence to Adjuvant Imatinib Therapy in Patients with Gastrointestinal Stromal Tumor in Clinical Practice: A Cross-Sectional Study

28. Probabilistic medicine: a pre-emptive approach is needed for cancer therapeutic risk mitigation

29. An Initial Genetic Analysis of Gemcitabine-Induced High-Grade Neutropenia in Pancreatic Cancer Patients in CALGB 80303 (Alliance)

30. The National Cancer Institute Clinical Trials Planning Meeting for Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy

31. Propranolol induced G0/G1/S phase arrest and apoptosis in melanoma cells via AKT/MAPK pathway

32. Treatment trends with immune checkpoint inhibitor (ICI) therapy in older adults with lung cancer

33. Genetic variation determines VEGF-A plasma levels in cancer patients

34. Cancer pharmacogenomics, adoption by oncologists and patient benefit

35. Value of Supportive Care Pharmacogenomics in Oncology Practice

36. The relationship between miR-302b and EphA2 and their clinical significance in gastric cancer

37. The Impact of Skeletal Muscle on the Pharmacokinetics and Toxicity of 5-Fluorouracil in Colorectal Cancer

38. Research Directions in Genetic Predispositions to Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis

39. Prediction of chemotherapy-induced nausea and vomiting from patient-reported and genetic risk factors

40. Incidence and triggers of Stevens-Johnson syndrome and toxic epidermal necrolysis in a large cancer patient cohort

41. EBV infection and MSI status significantly influence the clinical outcomes of gastric cancer patients

42. Discordance of somatic mutations between Asian and Caucasian patient populations with gastric cancer

43. Quantitation of Targetable Somatic Mutations Among Patients Evaluated by a Personalized Medicine Clinical Service: Considerations for Off-Label Drug Use

44. Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance)

45. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Rasburicase Therapy in the Context of G6PD Deficiency Genotype

46. Epigenetic perspectives on cancer chemotherapy response

47. Polygenic inheritance of paclitaxel-induced sensory peripheral neuropathy driven by axon outgrowth gene sets in CALGB 40101 (Alliance)

48. Geographic variation in molecular subtype for gastric adenocarcinoma

49. Economic benefits of adaptive abiraterone therapy for advanced prostate cancer

50. ARID1a as a marker of prognosis and increased sensitivity to CDK4/6, mTOR 1/2 and Src homology region 2 phosphatase (SHP 1/2) inhibitors in breast cancer (BC)